Nih
Nih funding pages collect matching grants, scholarships, benefits, fellowships, and other programs from the FindMyMoney.App directory. Use this page to compare current opportunities, then verify deadlines and eligibility on the official source before applying.
RFA-EY-25-001: BRAIN Initiative: New Concepts and Early-Stage Research for Recording and Modulation in the Nervous System (R21) (Clinical Trial Not Allowed)
NIH’s BRAIN Initiative R21 NOFO supports early-stage, high-risk technologies for neural recording and modulation with up to $400,000 total direct costs over up to three years and a strong 2026 cycle due date still open as of 2026-05-31.
RFA-HD-27-007: Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research
This NIH RFA requests grant applications that use existing HIV/AIDS archives and biospecimen repositories to generate high-impact research on maternal and pediatric HIV outcomes.
RFA-HD-27-012: Limited Competition: Intellectual and Developmental Disabilities Research Centers 2027 (P50 Clinical Trial Optional)
A limited-competition NIH renewal for existing NICHD IDDRCs, this NOFO funds interdisciplinary P50 centers advancing translational, biomarker, and real-world research for intellectual and developmental disabilities.
RFA-HG-25-009: Supporting Talented Early Career Researchers in Genomics (R01)
NIH/NHGRI reissues an R01-style NOFO for highly promising Early Stage Investigators (ESIs) building independent genomics programs, with a maximum direct-cost budget of $400,000 per year and up to a five-year project term.
RFA-HL-26-003: NHLBI Emerging Investigator Award (EIA) (R35, Clinical Trial Optional)
NIH’s NHLBI Emerging Investigator Award (R35, clinical trial optional) supports established HLBS investigators with at least two NHLBI R01-equivalent grants for up to seven years of flexible, program-level funding, with the next listed due date on 19 February 2027.
RFA-HL-26-012: NIH StARR (R38) 2026-2027 Funding for Residency Research Programs
NIH StARR (R38) supports residency programs that give postdoctoral-level clinicians mentored research time and a path toward clinician-investigator careers.
RFA-HL-26-016: Catalyze Enabling Technologies and Transformative Platforms for HLBS Research (R33)
NIH's NHLBI Catalyze R33 opportunity funds enabling technologies and transformative platforms in heart, lung, blood, and sleep (HLBS) research with strong validation milestones and measurable performance measures.
RFA-HL-26-017: NIH Catalyze Product Definition for Small Molecules and Biologics (R61/R33)
NIH's RFA-HL-26-017 supports early-stage translational projects that generate and validate therapeutic candidates for HLBS diseases through a phased R61/R33 development pathway.
RFA-HL-26-019: Catalyze Product Definition - Medical Device Prototype Design/Testing, Diagnostics, and Assay Development (R61/R33)
NIH NHLBI Catalyze Product Definition NOFO for phased R61/R33 support of early-stage device, diagnostic, and assay development (clinical trials not allowed), with ongoing application rounds in 2026 and 2027.
RFA-HL-26-020: Catalyze: Product Definition Medical Device Prototype Optimization (R33)
NHLBI Catalyze RFA-HL-26-020 funds late-stage prototype optimization for medical devices, diagnostics, and research tools for heart, lung, blood, and sleep disorders via R33 awards.